NORVIR SEC CAPSULE

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

RITONAVIR

Inapatikana kutoka:

ABBVIE CORPORATION

ATC kanuni:

J05AE03

INN (Jina la Kimataifa):

RITONAVIR

Kipimo:

100MG

Dawa fomu:

CAPSULE

Tungo:

RITONAVIR 100MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

120

Dawa ya aina:

Prescription

Eneo la matibabu:

HIV PROTEASE INHIBITORS

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0128780001; AHFS:

Idhini hali ya:

CANCELLED POST MARKET

Idhini ya tarehe:

2014-11-25

Tabia za bidhaa

_ _
_NORVIR_
_®_
_, NORVIR_
_®_
_ SEC Product Monograph _
_Page 1 of 78 _
_Date of Revision: June 13, 2014 and Control No. 173634 _
PRODUCT MONOGRAPH
PR
NORVIR
®
Ritonavir
film-coated tablets (100 mg)
PR
NORVIR
®
Ritonavir
oral solution (80 mg/mL)
PR
NORVIR
®
SEC
Ritonavir
soft elastic capsules (100 mg)
Human Immunodeficiency Virus (HIV) Protease Inhibitor
AbbVie Corporation
Date of Revision:
8401 Trans-Canada Highway
July 21, 2014
St-Laurent, Qc H4S 1Z1
Submission Control No: 173634
_ _
_NORVIR_
_®_
_, NORVIR_
_®_
_ SEC Product Monograph _
_Page 2 of 78 _
_Date of Revision: June 13, 2014 and Control No. 173634 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE REACTIONS
..................................................................................................14
DRUG INTERACTIONS
..................................................................................................23
DOSAGE AND ADMINISTRATION
..............................................................................34
OVERDOSAGE
................................................................................................................37
ACTION AND CLINICAL PHARMACOLOGY
............................................................37
STORAGE AND STABILITY
..........................................................................................42
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................43
PART II: SCIENTIFIC INFORMATION
.............................................................